Evidence map›Paper›PMID 39554094›Full record

ArticlebioRxiv : the preprint server for biology2024

Mapping intratumoral myeloid-T cell interactomes at single-cell resolution reveals targets for overcoming checkpoint inhibitor resistance.

Kate Bridges, Gabriela A Pizzurro, Alev Baysoy, Janani P Baskaran, Ziyan Xu, Varsha Mathew, Victoria Tripple, Michael LaPorte, Koonam Park, William Damsky and 5 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kate BridgesDepartment of Biomedical Engineering, Yale University, New Haven, CT 06511, USA.ORCID 0000-0003-3642-7068
Gabriela A PizzurroDepartment of Biomedical Engineering, Yale University, New Haven, CT 06511, USA.ORCID 0000-0002-1193-9385
Alev BaysoyDepartment of Biomedical Engineering, Yale University, New Haven, CT 06511, USA.ORCID 0000-0001-5526-5848
Janani P BaskaranDepartment of Biomedical Engineering, Yale University, New Haven, CT 06511, USA.ORCID 0000-0002-4764-9611
Ziyan XuNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA 92037, USA.ORCID 0000-0003-1270-135X
Varsha MathewNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA 92037, USA.ORCID 0009-0003-9801-0513
Victoria TrippleNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
Michael LaPorteNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
Koonam ParkDepartment of Dermatology, Yale School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0001-5480-3915
William DamskyDepartment of Dermatology, Yale School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0003-0975-4071
Harriet KlugerDepartment of Medicine (Medical Oncology), Yale School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0002-4932-9873
Rong FanDepartment of Biomedical Engineering, Yale University, New Haven, CT 06511, USA.ORCID 0000-0001-7805-8059
Susan M KaechNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA 92037, USA.ORCID 0000-0003-1674-1420
Marcus W BosenbergDepartment of Dermatology, Yale School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0003-0166-1612
Kathryn Miller-JensenDepartment of Biomedical Engineering, Yale University, New Haven, CT 06511, USA.ORCID 0000-0002-7233-0100

Funding

Systems analysis of cell-cell communication networks and immune activity in the melanoma tumor microenvironmentU01CA238728 · NCI · YALE UNIVERSITY · PI BOSENBERG, MARCUS W, MILLER-JENSEN, KATHRYN · 2020 to 2024
$2.9M
NCI NIH HHS U01 CA238728
6 · The paper itself

Abstract

Effective cancer immunotherapies restore anti-tumor immunity by rewiring cell-cell communication. Treatment-induced changes in communication can be inferred from single-cell RNA-sequencing (scRNA-seq) data, but current methods do not effectively manage heterogeneity within cell types. Here we developed a computational approach to efficiently analyze scRNA-seq-derived, single-cell-resolved cell-cell interactomes, which we applied to determine how agonistic CD40 (CD40ag) alters immune cell crosstalk alone, across tumor models, and in combination with immune checkpoint blockade (ICB). Our analyses suggested that CD40ag improves responses to ICB by targeting both immuno-stimulatory and immunosuppressive macrophage subsets communicating with T cells, and we experimentally validated a spatial basis for these subsets with immunofluorescence and spatial transcriptomics. Moreover, treatment with CD40ag and ICB established coordinated myeloid-T cell interaction hubs that are critical for reestablishing antitumor immunity. Our work advances the biological significance of hypotheses generated from scRNA-seq-derived cell-cell interactomes and supports the clinical translation of myeloid-targeted therapies for ICB-resistant tumors.

Indexed as

cancer immunotherapycell-cell communicationimmune checkpoint blockademregDCssingle-cell RNA-sequencing (scRNA-seq)spatial transcriptomicstumor-associated macrophagestumor microenvironment (TME)

Identifiers

PMID39554094
PMCPMC11565996

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.